BioVersys Secures Chinese Patent for BV100 Technology

BioVersys AG, a biopharmaceutical company based in Basel, Switzerland, announced the granting of a significant patent by the Chinese Patent Office for its BV100 drug candidate. This development expands the patent coverage of BV100, now protected in over 25 countries including the US, Europe, UK, and China.

BV100 represents an advanced formulation of rifabutin for intravenous use, aimed at treating severe hospital infections caused by Acinetobacter baumannii, particularly carbapenem-resistant strains. These infections pose a high mortality risk, with rates reaching up to 50% in hospitals.

China, experiencing high incidences and resistance rates for Acinetobacter infections, hosts a potential patient base exceeding one million annually. BioVersys aims to conduct Phase 1 trials in China, integrating it into their global registration trial for BV100, aligning with their strategic market expansion goals.